cas 20535-83-5|| where to buy 6-Methoxy-9H-purin-2-amine

Nombre del producto:6-Methoxy-9H-purin-2-amine

IUPAC Name:6-methoxy-7H-purin-2-amine

Unidad de embalaje	Stock disponible	Precio($)
CM138582-10g	in stock	Ǡş
CM138582-25g	in stock	ǆŸ
CM138582-100g	in stock	ȋƅǆ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 20535-83-5 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :20535-83-5; Fórmula molecular:C6H7N5O; Punto de fusión:-; Código de sonrisas:COC1=NC(N)=NC2=C1NC=N2; Densidad:

: Número de catálogo:CM138582; Peso molecular:165.16; Punto de ebullición:598.5°C at 760 mmHg; Nº Mdl:MFCD00133009; Almacenamiento:Keep in a tight container and store at ambient temperature，protect from light

: Purines; Purines are heterocyclic aromatic compounds composed of linked pyrimidine and imidazole rings. In mammals, purines are most commonly expressed in DNA and RNA (including the purines adenine and guanine), as well as single-molecule nucleotides (adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), cyclic AMP, and to a lesser extent guanosine triphosphate (GTP) and cyclic guanosine monophosphate (cGMP). Purines are also key elements of the following energy metabolism molecules: reduced nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate (NADPH), and coenzyme Q. Purines can also act as direct neurotransmitters; for example, adenosine may interact with receptors to modulate cardiovascular and central nervous system (CNS) function.; purine wholesale; Find trusted purine wholesaler. Any requirements and problems can ask us at any time.

: Ibezapolstat; Acurx announces successful FDA end-of-phase 2 meeting and phase 3 readiness for Ibezapolstat in the treatment of C. difficile infection. The successful meeting outcomes include reaching key elements of Phase 3 clinical trial program and a development plan of NDA filling. C. difficile infection (CDI) is a bacterial infection of the colon, and causes diarrhea and colitis.
Ibezapolstat is a novel antibacterial agent that acts specially on DNA pol IIIC enzyme through competitive inhibition of dGTP (guanosine analog). Ibezapolstat has been granted Fast Track Designation from the U.S. FDA.